NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSBiotechnology
+$0.12 today
- Market cap
- $2.37B
- Beta
- 0.08
- P/E (TTM)
- -17.2
- EPS (TTM)
- -$1.76
Volume 1.80M
Average 1.21M
NAMS EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
NewAmsterdam Pharma Company N.V.NASDAQ: NAMS
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) remains negative
Q2 FY2026 EPS (Diluted) was -$0.52, compared with -$0.15 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.18.
Context
- EPS (Diluted) grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 9 analysts of -$1.54 (+12.3%) for the fiscal year ending Dec 2026, a slowdown from the +31.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$0.52-30.0% QoQ
- Last fiscal yearDec 2025
- -$1.75+31.6% YoY
- LTMJun 2026
- -$2.18-32.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -246.7% | +22.7% | +269.3 pp |
| 1 year | +31.6% | +12.3% | -19.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.75) USD
- Year-over-year change
- +31.6%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.75) | +31.6% |
| FY2024 | 2024-12-31 | (2.56) | -19.1% |
| FY2023 | 2023-12-31 | (2.15) | -80.7% |
| FY2022 | 2022-12-31 | (1.19) | +64.4% |
| FY2021 | 2021-12-31 | (3.34) | — |
EPS (Diluted) vs competitors
How NAMS compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -32.1% is the 8th highest of 9, against a peer median of +1.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| FY2025 | -A$1.14 AUD | +63.5% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$1.29 USD | +14.6% | — |
| LTM Sep 2026 | -$1.42 USD | +21.1% | — | |
| LTM Mar 2026 | -$1.87 USD | +3.6% | — | |
| LTM Jun 2026 | -$2.18 USD | -32.1% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$2.4 USD | -18.2% | — |
| LTM Jun 2026 | -$2.84 USD | -1.4% | — | |
| LTM Jun 2026 | -$4.66 USD | -204.6% | — | |
| LTM Jun 2026 | -$12.89 USD | -0.3% | — | |
| Peer median (excluding NAMS) | — | +1.6% | — | |
Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 102.69M | 14.09M | 45.56M | 22.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 59K |
| Gross Profit | 0 | 102.69M | 14.09M | 45.56M | 22.44M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 99.7% |
| Research & Development | 28.97M | 86.74M | 159.42M | 151.41M | 141.83M |
| Selling, General & Admin | 5.68M | 19.51M | 37.63M | 70.45M | 106.3M |
| Operating Expenses | 34.98M | 106.25M | 197.06M | 221.85M | 248.13M |
| Depreciation & Amortization | 5K | 9K | 49K | 113K | 220K |
| EBITDA | (41.37M) | (22.34M) | (176.86M) | (241.49M) | (242.33M) |
| EBITDA Margin | — | -21.8% | -1255.2% | -530.0% | -1076.9% |
| Operating Income | (34.98M) | (3.56M) | (182.97M) | (176.29M) | (225.68M) |
| Operating Margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
| Interest Income | 0 | 0 | 10.22M | 16.88M | 27.59M |
| Interest Expense | 411K | 287K | 6.8M | 0 | 0 |
| Other Income / Expenses | (6.81M) | (19.08M) | 6.06M | (65.31M) | 21.86M |
| Income Before Tax | (41.79M) | (22.63M) | (176.91M) | (241.6M) | (203.82M) |
| Pre-Tax Margin | — | -22.0% | -1255.6% | -530.3% | -905.7% |
| Income Tax Expense | 0 | 0 | 27K | (1K) | 0 |
| Net Income | (41.79M) | (22.63M) | (176.94M) | (241.6M) | (203.82M) |
| Net Margin | — | -22.0% | -1255.8% | -530.3% | -905.7% |
| EPS (Basic) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| EPS (Diluted) | (3.34) | (1.19) | (2.15) | (2.56) | (1.75) |
| Weighted Avg Shares | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
| Weighted Avg Shares (Diluted) | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M |
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
Intrinsic Alpha fair value
Locked
Current Price
$19.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.